Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$772.7 million.

  • Century Therapeutics' Retained Earnings fell 354.75% to -$772.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$772.7 million, marking a year-over-year decrease of 354.75%. This contributed to the annual value of -$782.3 million for FY2024, which is 1930.03% down from last year.
  • Latest data reveals that Century Therapeutics reported Retained Earnings of -$772.7 million as of Q3 2025, which was down 354.75% from -$738.3 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Retained Earnings high stood at -$425.7 million for Q1 2022, and its period low was -$782.3 million during Q4 2024.
  • For the 4-year period, Century Therapeutics' Retained Earnings averaged around -$629.3 million, with its median value being -$655.8 million (2023).
  • In the last 5 years, Century Therapeutics' Retained Earnings tumbled by 2929.04% in 2023 and then tumbled by 320.9% in 2025.
  • Century Therapeutics' Retained Earnings (Quarter) stood at -$519.1 million in 2022, then fell by 26.33% to -$655.8 million in 2023, then decreased by 19.3% to -$782.3 million in 2024, then rose by 1.23% to -$772.7 million in 2025.
  • Its Retained Earnings was -$772.7 million in Q3 2025, compared to -$738.3 million in Q2 2025 and -$705.8 million in Q1 2025.